Results 11 to 20 of about 581 (153)

A randomized study of solriamfetol for excessive sleepiness in narcolepsy [PDF]

Annals of Neurology, 2019
ObjectiveSolriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.MethodsPatients with narcolepsy with mean sleep latency <25 minutes on the Maintenance of Wakefulness Test (MWT), Epworth ...
Thorpy M. J., Shapiro C., Mayer G., Corser B. C., Emsellem H., Plazzi G., Chen D., Carter L. P., Wang H., Lu Y., Black J., Dauvilliers Y.   +11 more
core   +6 more sources

Solriamfetol for the Treatment of Excessive Sleepiness in OSA [PDF]

Chest, 2019
Background: Excessive sleepiness (ES) is a common symptom of OSA, which often persists despite primary OSA therapy. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of ES in adults with OSA.Methods: After 2 weeks of clinical titration (n = 174) and 2 weeks of stable dose administration (n = 148 ...
Patrick J. Strollo, Jan Hedner, Nancy Collop, Daniel G. Lorch, Dan Chen, Lawrence P. Carter, Yuan Lu, Lawrence Lee, Jed Black, Jean-Louis Pépin, Susan Redline, Markku Partinen, Olli Polo, Tarja Saaresranta, Jean-Louis Pépin, Christine Paschen, Jan Hedner, Lena Leissner, Bradley Block, Nancy Collop, Robert Doekel, Stephen Duntley, Guillermo Giangreco, Rachel Givelber, Andrew Krystal, Chitra Lal, Mitchell Lee, Daniel G. Lorch, James Maynard, Daniel Norman, Susan Redline, Russell Rosenberg, Vernon Rowe, Kathleen Sarmiento, Andrew Schreiber, Richard Schwab, David Seiden, Morteza Shamsnia, Patrick J. Strollo, J. Catesby Ware   +39 more
openaire   +3 more sources

Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial [PDF]

Human Psychopharmacology: Clinical and Experimental, 2022
AbstractObjectiveTo evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving performance in participants with narcolepsy.MethodsIn this randomised, double‐blind, placebo‐controlled, crossover study, driving performance during a 1 h on‐road driving test was assessed at 2 and 6 h post‐dose following 7 ...
Frederick Vinckenbosch, Gert Jan Lammers, Sebastiaan Overeem, Dan Chen, Grace Wang, Lawrence P. Carter, Kefei Zhou, Johannes G. Ramaekers, Annemiek Vermeeren   +8 more
openaire   +8 more sources

0763 Effects Of Solriamfetol On Driving Performance In Participants With Narcolepsy [PDF]

Sleep, 2020
Abstract Introduction Patients with narcolepsy have an increased risk of automobile accidents. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the US (Sunosi®) for adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75-150 mg/day). This study evaluated
Vinckenbosch, F., Lammers, G., Overeem, S., Chen, D., Wang, G., Carter, L., Zhou, K., Ramaekers, J., Vermeeren, A.   +8 more
openaire   +3 more sources

Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA [PDF]

Chest, 2021
Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, is approved in the United States to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with OSA (37.5-150 mg/d).Does solriamfetol have differential effects on EDS based on adherence to primary OSA therapy and does solriamfetol affect primary OSA therapy use ...
Schweitzer, Paula K, Mayer, Geert, Rosenberg, Russell, Malhotra, Atul, Zammit, Gary K, Gotfried, Mark, Chandler, Patricia, Baladi, Michelle, Strohl, Kingman P   +8 more
openaire   +6 more sources

Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database [PDF]

Frontiers in Pharmacology
ObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou, Jia Chen, Bangtian Xu, Li Chen, Li Chen, Li Chen   +5 more
doaj   +2 more sources

Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. [PDF]

Arthritis Rheumatol
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Hlavaty A, Dari L, Cracowski JL, Roustit M, Khouri C.   +4 more
europepmc   +2 more sources

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives

Nature and Science of Sleep, 2021
Vivien C Abad Department of Psychiatry & Behavioral Sciences, Division of Sleep Medicine, Stanford University, Redwood City, CA 94063, USACorrespondence: Vivien C AbadDepartment of Psychiatry & Behavioral Sciences Division of Sleep Medicine ...

exaly   +2 more sources

Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022. [PDF]

J Sleep Res
Summary Clinicians and people with narcolepsy report varied access to higher‐cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends
van Someren F, Wiedemann M, Warren-Gash C, Sykorova M, Mistry H, Miller MA, Leschziner G, Nolte E, Belot A, Smith IE, Quinnell T, Eriksson SH, Strongman H.   +12 more
europepmc   +2 more sources

Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea. [PDF]

Chronic Dis Transl Med
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Preshy A, Fernandez CJ, Nedai MH, Pappachan JM.   +3 more
europepmc   +2 more sources